Histogen — 2020 BIO Digital International Conference
19 slides from Histogen's conference presentation, Jun 5, 2020
Slide 1: Redefining Regenerative Medicine
Redefining Regenerative Medicine 2020 BIO DIGITAL INTERNATIONAL CONFERENCE June 8-11, 2020 Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbo
Slide 3: Corporate Overview
Corporate Overview Histogen A regenerative therapeutics company with a novel biological platform that replaces and regenerates tissues in the body Technology Our proprietary manufacturing process yields multiple biologic products from a single bioreactor. This innovative technology platform delivers
Slide 4: Histogen – Recent Highlights
Histogen – Recent Highlights Completed Merger with Conatus Pharmaceuticals on May 26, 2020 Cash to fund pipeline development Public listing on NASDAQ IND Approval and Initiation of Phase 1b/2a for HST 001 Cleared path to begin Phase 1b/2a trial in male androgenic alopecia First patient scheduled for
Slide 5: Summary of Key Merger Terms
Summary of Key Merger Terms Transaction closed on May 26, 2020 Structure: Reverse Triangular Merger Ownership: 74/26 split (Histogen / Conatus) Post-Merger Fully Diluted Shares: 13,194,116 NASDAQ Capital Market Listing: HSTO Board Representation: Histogen-6 and Contatus-2 David Crean Ph.D. – Chairma
Slide 6: HSC Hair Growth
HSC Hair Growth A minimally-invasive treatment to promote new hair growth where existing treatments only reduce hair loss
Slide 7: HST - Hair Growth US Market Opportunity
HST 001 - Hair Growth US Market Opportunity Addressable Market: $3.6 billion spent on hair loss, targeting men aged 30 – 491 Nature of Treatment: Minimally invasive HSC injections of 0.1mL throughout thinning area of the scalp, administered by dermatologists and cosmetic surgeons Market Growth: 2% p
Slide 8: HST Phase 1b/2a Protocol Summary
HST 001 Phase 1b/2a Protocol Summary Objective: To evaluate the safety and efficacy of HSC in male pattern hair loss Enrollment Criteria: 36 men, aged 20-55 Male Pattern Hair Loss identified as Norwood-Hamilton 2A, 3, 3V, 4,& 4A Treatment Regimen: 20 injections of HSC week 0, week 6, & week 12 20 in
Slide 9: hECM Fillers
hECM Fillers Human-derived collagen and extracellular matrix dermal fillers for delivering longer-lasting effects for the treatment of facial folds and wrinkles addressing a fast growing global market
Slide 10: HST - Dermal Filler US Market Opportunity
HST 002 - Dermal Filler US Market Opportunity Addressable Market: 1.2 million receiving dermal fillers,10 million considering dermal fillers1 Nature of Treatment: Lower face, cheek, and lip account for ~60% of treatments. Patients receive approximately 1.7 treatments per sitting Market Growth: 7% pe
Slide 11: HST Phase 1 Protocol Summary
HST 002 Phase 1 Protocol Summary Objective: Evaluate an all human extracellular matrix (hECM) as a dermal filler, in direct comparison to Restylane-L in moderate to severe nasolabial folds Enrollment Criteria: 22 subjects, men and women, with moderate to severe nasolabial folds 2 clinical sites Trea
Slide 12: hECM Joint Cartilage
hECM Joint Cartilage Histogen’s human extracellular matrix for regenerating hyaline cartilage for the treatment of articular cartilage defects with a novel malleable scaffold that stimulates the body’s own stem cells.
Slide 13: HST - Joint Cartilage US Market Opportunity
HST 003 - Joint Cartilage US Market Opportunity Addressable Market: 0.2 million receiving joint cartilage repair, 17.5 million considering joint cartilage repair1 Nature of Treatment: Patients receiving arthroscopic microfracture or cartilage transplant treatments due to acute injury and/or osteoart
Slide 14: HST - Preclinical Proof of Concept
HST 003 - Preclinical Proof of Concept In vivo efficacy in rat model Untreated defects (10): extensive fibrotic tissue and no articular cartilage at 6 weeks Treated defects (10): congruent and smooth cartilage regeneration and integration with surrounding cartilage at 6 weeks (O’Driscoll score p<0.0
Slide 15: HST - Phase 1 Protocol
HST 003 - Phase 1 Protocol Objective: Evaluate the safety of hECM paste delivered arthroscopically during microfracture procedure Enrollment Criteria: 12 subjects, men and women, who are candidates for microfracture surgery Recent focal cartilage defects of 2 - 4 cm2 in size in the knee 3 clinical s
Slide 16: Financial
Financial A track record of successful funding combined with prudent financial management provides the necessary foundation for growth
Slide 17: Financial Snapshot
Financial Snapshot* Histogen has raised approximately $20 million pre-merger to date through licensing transactions, with potential for an additional $10.5 million in future milestone payments under these licenses. Fully Diluted Shares: 13.2 MM NASDAQ Ticker: HSTO Shares Outstanding: 11.8 MM Market
Slide 18: Histogen – Positioned for Growth
Histogen – Positioned for Growth Validated Technology: Demonstrated pre-clinical/clinical POC with HSC and hECM CCM marketed by Allergan in their SkinMedica TNS A+ brand Strategic Pipeline: Targeting high-value markets with novel product candidates Clinical development programs designed to address s
Slide 19: Redefining Regenerative Medicine
Redefining Regenerative Medicine 2020 BIO DIGITAL INTERNATIONAL CONFERENCE June 8-11, 2020